'The biology of Interleukin-6 and its role in autoimmunity'
Cytokines receptors exist in membrane bound and soluble form. The IL-6/soluble IL-6R complex stimulates target cells not stimulated by IL-6 alone, since they do not express the membrane bound IL-6R. We have named this process ‘trans-signaling’. The soluble IL-6R is generated via ectodomain shedding by the membrane bound metalloprotease ADAM17. Soluble gp130 is the natural inhibitor of IL-6/soluble IL-6R complex responses. The dimerized recombinant soluble gp130Fc fusion protein is a molecular tool to discriminate between gp130 responses via membrane bound and soluble IL-6R responses.
Interestingly, depending on the animal model used, global blockade of IL-6 signaling by neutralizing monoclonal antibodies and selective blockade of IL-6 trans-signaling can lead to different consequences. Inhibition of IL-6 trans-signaling but not global IL-6 blockade was beneficial in several inflammation and cancer models. The extent of inflammation is controlled by trans-signaling via the soluble IL-6R. Using the sgp130Fc protein or sgp130Fc transgenic mice we demonstrate in animal models of inflammatory bowel disease, peritonitis, rheumatoid arthritis, atherosclerosis, pancreatitis, lupus erythematodes, colon cancer, ovarian cancer, pancreatic cancer, nephrotoxic nephritis and high fat diet induced obesity that IL-6 trans-signaling via the soluble IL-6R is the crucial step in the development and the progression of the disease. Therefore, sgp130Fc is a novel therapeutic agent for the treatment of chronic inflammatory diseases and cancer and it underwent phase I clinical trials as an anti-inflammatory in 2013/2014. Phase II clinical trials in patients with autoimmune diseases such as inflammatory bowel disease have started in 2016.
14 May 2018, 12:00 (Monday, 4th week, Trinity 2018)
Kennedy Institute of Rheumatology, Headington OX3 7FY
Bernard Sunley Lecture Theatre
Prof Stefan Rose-John ( Institute of Biochemistry, Kiel University)
Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS)
Professor Irina Udalova (Kennedy Institute of Rheumatology),
Jo Silva (NDORMS),
Wulf Forrester-Barker (University of Oxford, Nuffield Dept of Orthopaedics Rheumatology and Musculoskeletal Sciences)
Organiser contact email address:
Yoshi Itoh (ASSOCIATE PROFESSOR AND PRINCIPAL INVESTIGATOR CELL MIGRATION GROUP)
Kennedy Institute Seminars
Members of the University only